Chemed Corporation, publicly traded under the ticker "CHE", is a diversified corporation based in Cincinnati, Ohio, providing vital services in varying industries since its establishment in the late 1900s. The corporation operates two primary business segments: VITAS Healthcare and Roto-Rooter.
VITAS Healthcare, a subsidiary of Chemed, is the acknowledged leader in the American hospice care industry. This segment provides end-of-life care services for patients with critical and terminal illnesses, providing compassionate, advanced illness care to patients and families. These services are administered by a dedicated team of registered nurses, home health aides, social workers, physicians, and volunteers, who deliver quality palliative care in the comfort of the patient's home or other settings such as hospitals, nursing homes, and assisted living communities. VITAS maintains a significant presence nationwide and serves a majority of the metropolitan regions.
The Roto-Rooter business segment, on the other hand, offers a wide array of plumbing, sewer, and drain cleaning services. It is recognized as the largest provider of these services in the United States and Canada, operating in both residential and commercial markets. This division is backed by a team of trained professionals who undertake jobs ranging from basic maintenance and repairs to larger-scale installations.
Chemed Corporation, under the leadership of CEO Kevin J. McNamara, is also committed to corporate social responsibility with initiatives such as Environment, Health, and Safety (EHS) programs focusing on the wellness of its employees, and the Charity Program, where it financially supports numerous charitable causes.
Chemed's strong financial footing has been confirmed by their consistent annual reports showing stable revenue generation and operating income growth. The corporation's financial robustness has been largely driven by the organic growth of its existing businesses and the strategic acquisitions of related businesses.
Despite being in diverse business sectors, Chemed Corporation has successfully established itself as a market leader in both healthcare and service industries. The corporation's unwavering commitment to quality service and its innovative approach to business has solidified its reputation and continues to drive its growth in the market.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Chemed (CHE) has reported higher net income and earnings per share for Q3 and the first nine months of 2026, leading to a share price of US$528.05 and a year-to-date return of 24.6%. Analysts view Chemed as 21.8% undervalued with a fair value of $675, citing growth drivers in both its VITAS hospice care and Roto-Rooter plumbing services, though potential risks exist in Medicare Cap setbacks and rising digital lead costs. Investors are encouraged to assess the company's valuation against both its growth prospects and these identified risks.

Alps Advisors Inc. significantly reduced its holdings in Chemed Corporation by 24% in the third quarter, selling 9,809 shares and ending with 30,986 shares valued at $15.65 million. Despite insider selling by executives, Chemed reported strong quarterly results, beating EPS consensus and increasing revenue by 10.6% year over year. The stock currently holds an average analyst rating of "Hold" with a target price of $603.00.

Chemed Corporation (NYSE: CHE) announced a quarterly dividend of $0.70 per share, maintaining its previous payout. The company is considered modestly undervalued by GuruFocus' GF Value™ and has a strong GF Score™ of 86/100, reflecting solid financial health and profitability, despite recent net insider selling.

ProShare Advisors LLC significantly reduced its stake in Chemed Corporation by 23.3% in the third quarter, selling 16,516 shares and retaining 54,245 shares valued at approximately $27.4 million. Despite institutional ownership by 95.85% of the stock, analyst sentiment is mixed but improving, with a consensus "Hold" rating and an average target price of $603. Chemed reported strong quarterly earnings, beating estimates, with revenue up 10.6% year-over-year, and increased its quarterly dividend to $0.70 per share.